Review



tkis nilotinib  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress tkis nilotinib
    Tkis Nilotinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 47 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tkis nilotinib/product/MedChemExpress
    Average 94 stars, based on 47 article reviews
    tkis nilotinib - by Bioz Stars, 2026-06
    94/100 stars

    Images



    Similar Products

    94
    MedChemExpress tkis nilotinib
    Tkis Nilotinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tkis nilotinib/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    tkis nilotinib - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    93
    Selleck Chemicals anti second-generation bcr-abl tkis
    Anti Second Generation Bcr Abl Tkis, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti second-generation bcr-abl tkis/product/Selleck Chemicals
    Average 93 stars, based on 1 article reviews
    anti second-generation bcr-abl tkis - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc tyrosine kinase inhibitors (tkis) nilotinib 12209
    Tyrosine Kinase Inhibitors (Tkis) Nilotinib 12209, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tyrosine kinase inhibitors (tkis) nilotinib 12209/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    tyrosine kinase inhibitors (tkis) nilotinib 12209 - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Novartis nilotinib tki
    Nilotinib Tki, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nilotinib tki/product/Novartis
    Average 90 stars, based on 1 article reviews
    nilotinib tki - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    94
    Selleck Chemicals nilotinib tki
    Nilotinib Tki, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nilotinib tki/product/Selleck Chemicals
    Average 94 stars, based on 1 article reviews
    nilotinib tki - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    90
    Novartis nilotinib (tki)
    (A) Experimental schema. BCR-ABL expression was induced in SCL-tTA-BCR-ABL mice (CML) by tetracycline withdrawal. WBM cells obtained 8 weeks after leukemia induction from CML mice and from WT healthy mice (normal) were injected into WT mice irradiated at 8 Gy (n = 6–8 mice/group). Mice were treated 8 weeks after transplantation with Veh, CXCR2i (5 mg/kg), Nil (50 mg/kg), or the combination once daily by oral gavage for 2 weeks, after which they were euthanized and PB and BM were analyzed by flow cytometry. (B–D) WBC numbers (B) and neutrophil frequency (C) in the PB and LSC numbers in (D) in the BM (2 femora + 2 tibiae) of CML mice. (E) A cohort of mice was followed for survival after stopping treatment (n = 7–8 mice/group). After primary transplantation of CML WBM cells from (A), LTHSCs were FACS-purified and transplanted into secondary healthy WT mice irradiated at 800 cGy. (F) Serial blood draw was performed every 4 weeks until 16 weeks. (G) WBM cells from Cxcr2 +/+ -SCL-tTA-BCR-ABL or Cxcr2 −/− -SCL-tTA-BCR-ABL double-mutant mice (2 × 10 6 cells/mouse, n = 6–8 mice/group) were injected into WT mice irradiated at 8 Gy (n = 6–8 mice/group). Transplanted mice were maintained off doxycycline to induce BCR-ABL expression and generate leukemia. Mice were treated 8 weeks after transplantation with Veh or Nil (50 mg/kg) once daily by oral gavage for 2 weeks and euthanized, and PB and BM were analyzed by flow cytometry. (H–K) Total WBC (H) and frequency of multi-lineage reconstitution of donor cells (I) in the PB and numbers of donor LSCs (J) and GMP (K) in the BM (2 femora + 2 tibiae). (L) Primary human CML CD34+ cells were labeled with CFSE, and CFSE max CD34+CD38− primitive LSCs were FACS purified and co-cultured with or without primary human BM MSC (hMSCs) with <t>nilotinib</t> (Nil; 1 μM), the CXCR2i (10 μM), or both or were left untreated for 72 h (n = 4 biological replicates). The proliferation index was calculated on the basis of reduction in CFSE levels. (M and N) The effects of treatment on the proliferation index in the presence of hMSC cells (M) and the percentage of apoptosis, calculated based on Annexin V+ labeling, of CML cells in the presence of hMSCs (N) are shown. (O) Annexin V+ labeling of murine LSCs cocultured in the presence of CML 6C3+ cells and treated with various drugs for 48 h. Error bars represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
    Nilotinib (Tki), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nilotinib (tki)/product/Novartis
    Average 90 stars, based on 1 article reviews
    nilotinib (tki) - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Novartis exogenous tyrosine kinase inhibitor (tki) nilotinib
    (A) Experimental schema. BCR-ABL expression was induced in SCL-tTA-BCR-ABL mice (CML) by tetracycline withdrawal. WBM cells obtained 8 weeks after leukemia induction from CML mice and from WT healthy mice (normal) were injected into WT mice irradiated at 8 Gy (n = 6–8 mice/group). Mice were treated 8 weeks after transplantation with Veh, CXCR2i (5 mg/kg), Nil (50 mg/kg), or the combination once daily by oral gavage for 2 weeks, after which they were euthanized and PB and BM were analyzed by flow cytometry. (B–D) WBC numbers (B) and neutrophil frequency (C) in the PB and LSC numbers in (D) in the BM (2 femora + 2 tibiae) of CML mice. (E) A cohort of mice was followed for survival after stopping treatment (n = 7–8 mice/group). After primary transplantation of CML WBM cells from (A), LTHSCs were FACS-purified and transplanted into secondary healthy WT mice irradiated at 800 cGy. (F) Serial blood draw was performed every 4 weeks until 16 weeks. (G) WBM cells from Cxcr2 +/+ -SCL-tTA-BCR-ABL or Cxcr2 −/− -SCL-tTA-BCR-ABL double-mutant mice (2 × 10 6 cells/mouse, n = 6–8 mice/group) were injected into WT mice irradiated at 8 Gy (n = 6–8 mice/group). Transplanted mice were maintained off doxycycline to induce BCR-ABL expression and generate leukemia. Mice were treated 8 weeks after transplantation with Veh or Nil (50 mg/kg) once daily by oral gavage for 2 weeks and euthanized, and PB and BM were analyzed by flow cytometry. (H–K) Total WBC (H) and frequency of multi-lineage reconstitution of donor cells (I) in the PB and numbers of donor LSCs (J) and GMP (K) in the BM (2 femora + 2 tibiae). (L) Primary human CML CD34+ cells were labeled with CFSE, and CFSE max CD34+CD38− primitive LSCs were FACS purified and co-cultured with or without primary human BM MSC (hMSCs) with <t>nilotinib</t> (Nil; 1 μM), the CXCR2i (10 μM), or both or were left untreated for 72 h (n = 4 biological replicates). The proliferation index was calculated on the basis of reduction in CFSE levels. (M and N) The effects of treatment on the proliferation index in the presence of hMSC cells (M) and the percentage of apoptosis, calculated based on Annexin V+ labeling, of CML cells in the presence of hMSCs (N) are shown. (O) Annexin V+ labeling of murine LSCs cocultured in the presence of CML 6C3+ cells and treated with various drugs for 48 h. Error bars represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
    Exogenous Tyrosine Kinase Inhibitor (Tki) Nilotinib, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/exogenous tyrosine kinase inhibitor (tki) nilotinib/product/Novartis
    Average 90 stars, based on 1 article reviews
    exogenous tyrosine kinase inhibitor (tki) nilotinib - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) Experimental schema. BCR-ABL expression was induced in SCL-tTA-BCR-ABL mice (CML) by tetracycline withdrawal. WBM cells obtained 8 weeks after leukemia induction from CML mice and from WT healthy mice (normal) were injected into WT mice irradiated at 8 Gy (n = 6–8 mice/group). Mice were treated 8 weeks after transplantation with Veh, CXCR2i (5 mg/kg), Nil (50 mg/kg), or the combination once daily by oral gavage for 2 weeks, after which they were euthanized and PB and BM were analyzed by flow cytometry. (B–D) WBC numbers (B) and neutrophil frequency (C) in the PB and LSC numbers in (D) in the BM (2 femora + 2 tibiae) of CML mice. (E) A cohort of mice was followed for survival after stopping treatment (n = 7–8 mice/group). After primary transplantation of CML WBM cells from (A), LTHSCs were FACS-purified and transplanted into secondary healthy WT mice irradiated at 800 cGy. (F) Serial blood draw was performed every 4 weeks until 16 weeks. (G) WBM cells from Cxcr2 +/+ -SCL-tTA-BCR-ABL or Cxcr2 −/− -SCL-tTA-BCR-ABL double-mutant mice (2 × 10 6 cells/mouse, n = 6–8 mice/group) were injected into WT mice irradiated at 8 Gy (n = 6–8 mice/group). Transplanted mice were maintained off doxycycline to induce BCR-ABL expression and generate leukemia. Mice were treated 8 weeks after transplantation with Veh or Nil (50 mg/kg) once daily by oral gavage for 2 weeks and euthanized, and PB and BM were analyzed by flow cytometry. (H–K) Total WBC (H) and frequency of multi-lineage reconstitution of donor cells (I) in the PB and numbers of donor LSCs (J) and GMP (K) in the BM (2 femora + 2 tibiae). (L) Primary human CML CD34+ cells were labeled with CFSE, and CFSE max CD34+CD38− primitive LSCs were FACS purified and co-cultured with or without primary human BM MSC (hMSCs) with nilotinib (Nil; 1 μM), the CXCR2i (10 μM), or both or were left untreated for 72 h (n = 4 biological replicates). The proliferation index was calculated on the basis of reduction in CFSE levels. (M and N) The effects of treatment on the proliferation index in the presence of hMSC cells (M) and the percentage of apoptosis, calculated based on Annexin V+ labeling, of CML cells in the presence of hMSCs (N) are shown. (O) Annexin V+ labeling of murine LSCs cocultured in the presence of CML 6C3+ cells and treated with various drugs for 48 h. Error bars represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

    Journal: Cell reports

    Article Title: TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling

    doi: 10.1016/j.celrep.2021.109386

    Figure Lengend Snippet: (A) Experimental schema. BCR-ABL expression was induced in SCL-tTA-BCR-ABL mice (CML) by tetracycline withdrawal. WBM cells obtained 8 weeks after leukemia induction from CML mice and from WT healthy mice (normal) were injected into WT mice irradiated at 8 Gy (n = 6–8 mice/group). Mice were treated 8 weeks after transplantation with Veh, CXCR2i (5 mg/kg), Nil (50 mg/kg), or the combination once daily by oral gavage for 2 weeks, after which they were euthanized and PB and BM were analyzed by flow cytometry. (B–D) WBC numbers (B) and neutrophil frequency (C) in the PB and LSC numbers in (D) in the BM (2 femora + 2 tibiae) of CML mice. (E) A cohort of mice was followed for survival after stopping treatment (n = 7–8 mice/group). After primary transplantation of CML WBM cells from (A), LTHSCs were FACS-purified and transplanted into secondary healthy WT mice irradiated at 800 cGy. (F) Serial blood draw was performed every 4 weeks until 16 weeks. (G) WBM cells from Cxcr2 +/+ -SCL-tTA-BCR-ABL or Cxcr2 −/− -SCL-tTA-BCR-ABL double-mutant mice (2 × 10 6 cells/mouse, n = 6–8 mice/group) were injected into WT mice irradiated at 8 Gy (n = 6–8 mice/group). Transplanted mice were maintained off doxycycline to induce BCR-ABL expression and generate leukemia. Mice were treated 8 weeks after transplantation with Veh or Nil (50 mg/kg) once daily by oral gavage for 2 weeks and euthanized, and PB and BM were analyzed by flow cytometry. (H–K) Total WBC (H) and frequency of multi-lineage reconstitution of donor cells (I) in the PB and numbers of donor LSCs (J) and GMP (K) in the BM (2 femora + 2 tibiae). (L) Primary human CML CD34+ cells were labeled with CFSE, and CFSE max CD34+CD38− primitive LSCs were FACS purified and co-cultured with or without primary human BM MSC (hMSCs) with nilotinib (Nil; 1 μM), the CXCR2i (10 μM), or both or were left untreated for 72 h (n = 4 biological replicates). The proliferation index was calculated on the basis of reduction in CFSE levels. (M and N) The effects of treatment on the proliferation index in the presence of hMSC cells (M) and the percentage of apoptosis, calculated based on Annexin V+ labeling, of CML cells in the presence of hMSCs (N) are shown. (O) Annexin V+ labeling of murine LSCs cocultured in the presence of CML 6C3+ cells and treated with various drugs for 48 h. Error bars represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

    Article Snippet: Nilotinib (TKI) supplied by Novartis Pharmaceuticals, and CXCR2 inhibitor (SB225002) purchased from Selleckchem (cat no. S7651, Houston, TX) were stored in 10mM dimethylsulfoxide (DMSO) at 20°C.

    Techniques: Expressing, Injection, Irradiation, Transplantation Assay, Flow Cytometry, Purification, Mutagenesis, Labeling, Cell Culture

    KEY RESOURCES TABLE

    Journal: Cell reports

    Article Title: TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling

    doi: 10.1016/j.celrep.2021.109386

    Figure Lengend Snippet: KEY RESOURCES TABLE

    Article Snippet: Nilotinib (TKI) supplied by Novartis Pharmaceuticals, and CXCR2 inhibitor (SB225002) purchased from Selleckchem (cat no. S7651, Houston, TX) were stored in 10mM dimethylsulfoxide (DMSO) at 20°C.

    Techniques: Recombinant, Flow Cytometry, DNA Library Preparation, RNA Sequencing, Software